NCT00478062

Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma

KGEL Vaccine After Initial Therapy of Hodgkin's Lymphoma

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Vaccines made from a tumor antigen may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I/II trial is studying the side effects and how well vaccine therapy works in treating patients who have received first-line therapy for Hodgkin's lymphoma.

Detailed description

OBJECTIVES: * Determine immunologic responses in patients who have completed first-line therapy for Hodgkin's lymphoma treated with Hodgkin's antigens-GM-CSF-expressing cell vaccine. * Determine the durability of these immunologic responses in these patients. * Determine the utility of an Epstein-Barr virus reporter system for monitoring cellular vaccine responses. * Determine the safety and tolerability of this vaccine in these patients. OUTLINE: Beginning 4-6 months after last chemotherapy, patients receive Hodgkin's antigens-GM-CSF-expressing cell vaccine on day 1. Treatment repeats every 3 weeks for up to 4 courses. Immunologic responses are serially monitored along with disease status. PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.

Conditions

• Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	Hodgkin's antigens-GM-CSF-expressing cell vaccine
PROCEDURE	adjuvant therapy

Timeline

• Start date: 2007-04-01
• Primary completion: 2008-06-01
• Completion: 2008-06-01
• First posted: 2007-05-24
• Last updated: 2018-02-28
• Results posted: 2018-02-28

Locations

1 site across 1 country: United States